Vutrisiran ATTR Cm denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for vutrisiran attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Vutrisiran ATTR Cm
## Why Cigna May Deny Vutrisiran (ATTR-CM) as Duplicate Therapy — and Why You Can Appeal
Vutrisiran (Amvuttra) is an FDA-approved RNA interference (RNAi) therapy for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). Cigna may issue a duplicate-therapy denial when it believes another approved ATTR therapy is already active on your profile — for example, a tafamidis prescription — and determines that concurrent use is duplicative. This denial type often arises from pharmacy claims data rather than clinical review, and it frequently does not reflect the actual clinical distinction between your current treatment and vutrisiran.
## Why This Denial Is Appealable
Duplicate-therapy determinations are made on the basis of drug class or mechanism, not individual patient circumstances. Under ACA §2719, you have the right to a full internal appeal. Under ERISA §503 (for employer-sponsored plans), you are entitled to a full-and-fair review. After a final internal denial, independent external review is available, typically within approximately four months. Expedited review (often resolved within 72 hours) is available when delay would seriously jeopardize your health — a strong argument in ATTR-CM, a progressive and life-threatening condition.
RNAi therapies and small-molecule stabilizers work by entirely different mechanisms, and your cardiologist is best positioned to explain the clinical rationale for the prescribed regimen. Cigna must evaluate that clinical evidence.
## What to Gather
- Diagnosis confirmation: Cardiac biopsy results, technetium nuclear imaging, genetic testing (if available), and cardiologist notes confirming ATTR-CM diagnosis and subtype (hereditary or wild-type).
- Current medication list: Documentation of all active ATTR-related therapies, with start dates and clinical rationale for each.
- Prescriber medical-necessity letter: A detailed letter from the treating cardiologist explaining the mechanism of vutrisiran, why the prescribed regimen is not clinically duplicative, and why it is necessary for your specific disease course.
- Clinical guidelines reference: Ask your cardiologist to reference the applicable guidance from the American College of Cardiology (ACC) or American Heart Association (AHA) regarding ATTR-CM management.
- Cigna coverage policy: Request Cigna's written medical policy for vutrisiran so you can address each criterion directly.
## Criteria-Mapping Structure
For each criterion Cigna cites in its duplicate-therapy determination, provide a direct clinical response:
> Cigna criterion: [paste verbatim] > Clinical response: [mechanism distinction, prescriber rationale, or chart fact]
## Timeline
File your internal appeal as soon as possible — confirm the exact deadline in your denial letter. Request expedited review in writing given the severity of ATTR-CM. After a final internal denial, file for external review without delay to preserve your rights.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →